Temporal intra-individual variation of immunological biomarkers in type 1 diabetes patients: Implications for future use in cross-sectional assessment

Ghanashyam Sarikonda, Jeremy Pettus, Sowbarnika Sachithanantham, Sonal Phatak, Jacqueline F. Miller, Lakshmi Ganesan, Ji Chae, Ronna Mallios, Steve Edelman, Bjoern Peters, Matthias Von Herrath

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Multiple immune parameters such as frequencies of autoreactive CD4+, CD8+ T-cells and CD4+CD25+Foxp3+ T-cells have been explored as biomarkers in human T1D. However, intra-individual temporal variation of these parameters has not been assessed systematically over time. We determined the variation in each of these parameters in a cohort of T1D and healthy donors (HDs), at monthly intervals for one year. Despite low intra- and inter-assay co-efficient of variation (CV), mean CVs for each of the immune parameters were 119.1% for CD4+ T-cell-derived IFN-?, 50.44% for autoreactive CD8+ T-cells, and 31.24% for CD4+CD25+Foxp3+ T-cells. Further, both HDs and T1D donors had similar CVs. The variation neither correlated with BMI, age, disease duration or insulin usage, nor were there detectable cyclical patterns of variation. However, averaging results from multiple visits for an individual provided a better estimate of the CV between visits. Based on our data we predict that by averaging values from three visits a treatment effect on these parameters with a 50% effect size could be detected with the same power using 1.8-4-fold fewer patients within a trial compared to using values from a single visit. Thus, our present data contribute to a more robust, accurate endpoint design for future clinical trials in T1D and aid in the identification of truly efficacious therapies. Copyright:

Original languageEnglish (US)
Article numbere79383
JournalPLoS One
Volume8
Issue number11
DOIs
StatePublished - Nov 4 2013

Fingerprint

T-cells
insulin-dependent diabetes mellitus
Biomarkers
Medical problems
Type 1 Diabetes Mellitus
biomarkers
T-lymphocytes
T-Lymphocytes
Tissue Donors
Assays
assays
endpoints
temporal variation
clinical trials
insulin
Clinical Trials
Insulin
therapeutics
duration
Therapeutics

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Temporal intra-individual variation of immunological biomarkers in type 1 diabetes patients : Implications for future use in cross-sectional assessment. / Sarikonda, Ghanashyam; Pettus, Jeremy; Sachithanantham, Sowbarnika; Phatak, Sonal; Miller, Jacqueline F.; Ganesan, Lakshmi; Chae, Ji; Mallios, Ronna; Edelman, Steve; Peters, Bjoern; Von Herrath, Matthias.

In: PLoS One, Vol. 8, No. 11, e79383, 04.11.2013.

Research output: Contribution to journalArticle

Sarikonda, G, Pettus, J, Sachithanantham, S, Phatak, S, Miller, JF, Ganesan, L, Chae, J, Mallios, R, Edelman, S, Peters, B & Von Herrath, M 2013, 'Temporal intra-individual variation of immunological biomarkers in type 1 diabetes patients: Implications for future use in cross-sectional assessment', PLoS One, vol. 8, no. 11, e79383. https://doi.org/10.1371/journal.pone.0079383
Sarikonda, Ghanashyam ; Pettus, Jeremy ; Sachithanantham, Sowbarnika ; Phatak, Sonal ; Miller, Jacqueline F. ; Ganesan, Lakshmi ; Chae, Ji ; Mallios, Ronna ; Edelman, Steve ; Peters, Bjoern ; Von Herrath, Matthias. / Temporal intra-individual variation of immunological biomarkers in type 1 diabetes patients : Implications for future use in cross-sectional assessment. In: PLoS One. 2013 ; Vol. 8, No. 11.
@article{53be00a3580b482aa1cbf26b37e2ec40,
title = "Temporal intra-individual variation of immunological biomarkers in type 1 diabetes patients: Implications for future use in cross-sectional assessment",
abstract = "Multiple immune parameters such as frequencies of autoreactive CD4+, CD8+ T-cells and CD4+CD25+Foxp3+ T-cells have been explored as biomarkers in human T1D. However, intra-individual temporal variation of these parameters has not been assessed systematically over time. We determined the variation in each of these parameters in a cohort of T1D and healthy donors (HDs), at monthly intervals for one year. Despite low intra- and inter-assay co-efficient of variation (CV), mean CVs for each of the immune parameters were 119.1{\%} for CD4+ T-cell-derived IFN-?, 50.44{\%} for autoreactive CD8+ T-cells, and 31.24{\%} for CD4+CD25+Foxp3+ T-cells. Further, both HDs and T1D donors had similar CVs. The variation neither correlated with BMI, age, disease duration or insulin usage, nor were there detectable cyclical patterns of variation. However, averaging results from multiple visits for an individual provided a better estimate of the CV between visits. Based on our data we predict that by averaging values from three visits a treatment effect on these parameters with a 50{\%} effect size could be detected with the same power using 1.8-4-fold fewer patients within a trial compared to using values from a single visit. Thus, our present data contribute to a more robust, accurate endpoint design for future clinical trials in T1D and aid in the identification of truly efficacious therapies. Copyright:",
author = "Ghanashyam Sarikonda and Jeremy Pettus and Sowbarnika Sachithanantham and Sonal Phatak and Miller, {Jacqueline F.} and Lakshmi Ganesan and Ji Chae and Ronna Mallios and Steve Edelman and Bjoern Peters and {Von Herrath}, Matthias",
year = "2013",
month = "11",
day = "4",
doi = "10.1371/journal.pone.0079383",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Temporal intra-individual variation of immunological biomarkers in type 1 diabetes patients

T2 - Implications for future use in cross-sectional assessment

AU - Sarikonda, Ghanashyam

AU - Pettus, Jeremy

AU - Sachithanantham, Sowbarnika

AU - Phatak, Sonal

AU - Miller, Jacqueline F.

AU - Ganesan, Lakshmi

AU - Chae, Ji

AU - Mallios, Ronna

AU - Edelman, Steve

AU - Peters, Bjoern

AU - Von Herrath, Matthias

PY - 2013/11/4

Y1 - 2013/11/4

N2 - Multiple immune parameters such as frequencies of autoreactive CD4+, CD8+ T-cells and CD4+CD25+Foxp3+ T-cells have been explored as biomarkers in human T1D. However, intra-individual temporal variation of these parameters has not been assessed systematically over time. We determined the variation in each of these parameters in a cohort of T1D and healthy donors (HDs), at monthly intervals for one year. Despite low intra- and inter-assay co-efficient of variation (CV), mean CVs for each of the immune parameters were 119.1% for CD4+ T-cell-derived IFN-?, 50.44% for autoreactive CD8+ T-cells, and 31.24% for CD4+CD25+Foxp3+ T-cells. Further, both HDs and T1D donors had similar CVs. The variation neither correlated with BMI, age, disease duration or insulin usage, nor were there detectable cyclical patterns of variation. However, averaging results from multiple visits for an individual provided a better estimate of the CV between visits. Based on our data we predict that by averaging values from three visits a treatment effect on these parameters with a 50% effect size could be detected with the same power using 1.8-4-fold fewer patients within a trial compared to using values from a single visit. Thus, our present data contribute to a more robust, accurate endpoint design for future clinical trials in T1D and aid in the identification of truly efficacious therapies. Copyright:

AB - Multiple immune parameters such as frequencies of autoreactive CD4+, CD8+ T-cells and CD4+CD25+Foxp3+ T-cells have been explored as biomarkers in human T1D. However, intra-individual temporal variation of these parameters has not been assessed systematically over time. We determined the variation in each of these parameters in a cohort of T1D and healthy donors (HDs), at monthly intervals for one year. Despite low intra- and inter-assay co-efficient of variation (CV), mean CVs for each of the immune parameters were 119.1% for CD4+ T-cell-derived IFN-?, 50.44% for autoreactive CD8+ T-cells, and 31.24% for CD4+CD25+Foxp3+ T-cells. Further, both HDs and T1D donors had similar CVs. The variation neither correlated with BMI, age, disease duration or insulin usage, nor were there detectable cyclical patterns of variation. However, averaging results from multiple visits for an individual provided a better estimate of the CV between visits. Based on our data we predict that by averaging values from three visits a treatment effect on these parameters with a 50% effect size could be detected with the same power using 1.8-4-fold fewer patients within a trial compared to using values from a single visit. Thus, our present data contribute to a more robust, accurate endpoint design for future clinical trials in T1D and aid in the identification of truly efficacious therapies. Copyright:

UR - http://www.scopus.com/inward/record.url?scp=84891915917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891915917&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0079383

DO - 10.1371/journal.pone.0079383

M3 - Article

C2 - 24223938

AN - SCOPUS:84891915917

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e79383

ER -